Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

December 5, 2013

— Data from Interim Analysis of Phase 2 Trial Provide Support to Advance Program —

— Interim Data Consistent with RPC1063 Differentiation Profile —

Software Industry Veteran Lou Shipley Named CEO of Black Duck Software

Software Industry Veteran Lou Shipley Named CEO of Black Duck Software

December 4, 2013

Extensive Experience in Cloud, Enterprise Software, Virtualization and CEO Roles Positions Black Duck for Accelerated Growth

Acceleron Pharma Provides Update on Clinical Pipeline at Piper Jaffray Healthcare Conference

Acceleron Pharma Provides Update on Clinical Pipeline at Piper Jaffray Healthcare Conference

December 3, 2013

Plans to initiate phase 2 study of dalantercept plus sorafenib in hepatocellular cancer in the first half of 2014

Remains on track to initiate pivotal trial with sotatercept or ACE-536 in late 2014 or early 2015

BIND Therapeutics Co-Founders Demonstrate Ability to Cross Biological Barriers with Targeted Therapeutic Nanoparticles

BIND Therapeutics Co-Founders Demonstrate Ability to Cross Biological Barriers with Targeted Therapeutic Nanoparticles

November 27, 2013

Data Published in Science Translational Medicine Offer Potential New Applications for BIND's Medicinal Nanoengineering Platform

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT

December 2, 2013

– Expands Company’s Therapeutic Pipeline for Infectious Diseases –

Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth

Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth

December 2, 2013

– Appoints David Arkowitz as Chief Operating Officer and Chief Financial Officer, and Greg Miller as Vice President of Business Development and Strategic Planning –

Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics

Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics

November 25, 2013

Company Founded by Five World Leaders in Genome Editing; Secures $43 Million Series A Financing Led by Flagship Ventures, Polaris Partners and Third Rock Ventures

Three VCs Pour $43M Into Editas to “Edit” Out Genetic Disorders

Three VCs Pour $43M Into Editas to “Edit” Out Genetic Disorders

November 25, 2013

Gene therapy, make way for gene “editing.”

Today, three of Boston’s biotech startup creators—Polaris Partners, Third Rock Ventures, and Flagship Ventures, have banded together to create a new, Cambridge, MA-based startup called Editas Medicine.

Avedro Announces FDA Priority Review Status for Corneal Cross-linking New Drug Application

Avedro Announces FDA Priority Review Status for Corneal Cross-linking New Drug Application

November 25, 2013

If Approved, Avedro Could Be Entitled to Seven Years Market Exclusivity

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro Inc, a Boston-based ophthalmic medical device and pharmaceutical company announces that it received notification from the U.S. Food and Drug Administration (FDA) stating that their NDA for riboflavin ophthalmic solution/KXL system has been filed, and has been granted priority review status. The priority review status places the application action date (PDUFA) at March 15th, 2014.

Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors

Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors

November 21, 2013

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that Stéphane Bancel, President and Founding Chief Executive Officer (CEO) of Moderna Therapeutics, and Senior Partner at Flagship Ventures, has joined its Board of Directors.